Recombinant protein · Immune activation, directed at Interleukin-2 receptor (high-affinity IL-2 receptor on CD8+ T cells and NK cells (IL2RA) · developed by Werewolf Therapeutics
Lecomkafusp alfa is a prodrug form of interleukin-2 (IL-2) with an inactivation domain linked by a tumor protease-sensitive linker and a half-life extension domain. IL-2 is released in the tumor microenvironment, where it binds high-affinity IL-2 receptors on CD8+ T cells and NK cells to activate them against tumor cells. It is being studied in metastatic and advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05479812 | Phase 1 | Metastatic Solid Tumor | Completed | HOWL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorMetastatic Solid Tumor
Updated Oct 18, 2026. Something wrong or missing? Report it on the HOWL page.
See HOWL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HOWL catalysts and pipeline →